TickerSutra

NSE: FORTIS · BSE: 532843 · ISIN INE061F01013

Fortis Healthcare Limited stock analysis

Fortis Healthcare Limited ranks #1725 in the TickerSutra evidence-ranked universe with a score of 51/100 and 95% data confidence. The latest captured fundamentals show ROCE of 13.4%, quarterly sales growth of 17.5% and quarterly profit growth of 3.4%.
Complete evidence gate pass governance reviewUpdated 29 Sept 2026
TICKERSUTRA SCORE51/100

Monitor only

#1725 of 5,430 ranked equities
Market capitalisation₹69,230.82cr
ROCE13.4%
Quarterly sales growth17.5%
Quarterly profit growth3.4%
P/E ratio64.9×
Promoter pledge0.0%

INVESTMENT EVIDENCE

What supports—and challenges—the thesis

Evidence in favour

  • CWIP indicates an active capacity pipeline
  • No promoter shares are reported as pledged

Risks and constraints

  • Valuation is above 40× earnings

Still unresolved: Related-party exposure · Broad media sentiment

FINANCIAL TRAJECTORY

Recent operating history

PeriodRevenueOperating profitNet profitOperating margin
2022₹5,718cr₹1,069cr₹790cr19.0%
2023₹6,298cr₹1,101cr₹633cr17.0%
2024₹6,893cr₹1,268cr₹645cr18.0%
2025₹7,783cr₹1,588cr₹809cr20.0%
2026₹9,128cr₹2,085cr₹1,064cr23.0%
TTM₹9,506cr₹2,131cr₹1,070cr22.0%
Debt / equity0.35×
CFO / EBITDA0.77×
Operating margin22.0%
Free cash flow₹673cr
Sales CAGR · 3Y13.2%
Profit CAGR · 3Y18.9%

EXCHANGE EVENT TRIGGERS

Latest corporate disclosures

0 positive catalysts0 negative catalysts11 routine filings

MANAGEMENT COMMENTARY

Signals from filed documents

Regulatory updatesLow severity · 6 mentions
Watch

But I think as far as, you know, the legalities of the whole process is concern ed, it was a fresh capital infusion through preferential allotment. All the necessary public disclosures and regulatory approval, shareholder approval, full public disclosures were done as far as IHH/NTK as well as RHT transaction is concerned. So, we are pretty sure that that is the case, and I think we will have to wait and see what hap

Regulatory approvalLow severity · 3 mentions
Watch

But I think as far as, you know, the legalities of the whole process is concern ed, it was a fresh capital infusion through preferential allotment. All the necessary public disclosures and regulatory approval, shareholder approval, full public disclosures were done as far as IHH/NTK as well as RHT transaction is concerned. So, we are pretty sure that that is the case, and I think we will have to wait and see what hap

Capacity expansion plansLow severity · 1 mention
Watch

Dilip, that IHH is fully, fully committed and is very bullish about India and the prospects of Fortis and the platform. Now as far as operations is concerned, all our plans which we have earlier mentioned about our brownfield expansion, the M&A activity, etc, those will continue to go as it is because we have already stated that it is internal accruals mainly which is going to d rive that part of the growth. Major M&

HOW TO READ THIS PAGE

Evidence, freshness and limitations

What does the TickerSutra score mean?

The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.

Which sources support this page?

Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.

Why can an item be unresolved?

Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.

Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer

DIRECTOR & BUSINESS NETWORK

Loading corporate intelligence

Loading universe coverage and exchange-backed evidence…